Abstract Number: 2006 • 2019 ACR/ARP Annual Meeting
Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis
Background/Purpose: Pyruvate kinase M2 (PKM2), one of glycolytic enzymes, is an emerging molecule that plays significant roles in tumor growth as well as inflammatory process.…Abstract Number: 2207 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis
Background/Purpose: To evaluate alterations of bone mineral density and microarchitecture in patients with rheumatoid arthritis (RA). We also aimed to identify potential factors associated with…Abstract Number: 2303 • 2019 ACR/ARP Annual Meeting
Emotional and Social Determinants of Health Increase Office Communication for Patients with Rheumatoid Arthritis
Background/Purpose: In RA patients, anxiety and depression are associated with higher disease activity and worse outcomes. We hypothesized that in RA patients, poorer mental health…Abstract Number: 2325 • 2019 ACR/ARP Annual Meeting
High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles
Background/Purpose: Patients with rheumatoid arthritis (RA) are at greater risk for cardiometabolic disease and early death. It is unclear if current anti-inflammatory pharmacotherapies alone are…Abstract Number: 2343 • 2019 ACR/ARP Annual Meeting
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…Abstract Number: 2806 • 2019 ACR/ARP Annual Meeting
Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). However, their heterogeneity remains poorly characterized.Methods:…Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…Abstract Number: 42 • 2019 ACR/ARP Annual Meeting
Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
Background/Purpose: Periodontitis and immune responses to periodontal pathogens such as Porphyromonas gingivalis (Pg) are associated with rheumatoid arthritis (RA) but the mechanisms underlying these connections…Abstract Number: 177 • 2019 ACR/ARP Annual Meeting
Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal
Background/Purpose: Work disability is a common consequence of Rheumatoid Arthritis (RA) with economic implications for both the patient and society. Scarce information is available on…Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…Abstract Number: 462 • 2019 ACR/ARP Annual Meeting
The Endogenous Plasma Small RNAome of Rheumatoid Arthritis
Background/Purpose: Small RNA (sRNA) sequencing has revealed new classes of sRNAs beyond microRNAs. These sRNAs can regulate genes and are also useful biomarkers of disease.…Abstract Number: 498 • 2019 ACR/ARP Annual Meeting
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 56
- Next Page »